It is FDA-approved for male pattern baldness and used off-label in some female cases
Not intended for direct intravenous injection without proper medication reconstitution or dilution
PharmaNutrition , 17 , 100263
Animal studies show co-administration of BPC-157 with NSAIDs almost completely prevented gastric lesion formation
Safety outcomes encompassed treatment-emergent and serious adverse events, the presence of anti-cagrilintide antibodies, and changes in blood pressure, pulse rate, high-sensitivity C-reactive protein, plasma renin activity, and aldosterone levels
The recommended 5-Amino-1MQ dosage for subcutaneous (subQ) injection ranges from 150-500 mcg daily